Hysbysiad dyfarnu contract
Canlyniadau'r weithdrefn gaffael
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
London School of Hygiene & Tropical Medicine
RC000330
Keppel Street,
London
WC1E 7HT
UK
Person cyswllt: Paul Pester
Ffôn: +44 02079272471
E-bost: paul.pester@lshtm.ac.uk
NUTS: UKI31
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: http://www.lshtm.ac.uk
Cyfeiriad proffil y prynwr: https://uk.eu-supply.com/ctm/Company/CompanyInformation/Index/104519
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Investigational Medicinial Product (IMP) & Placebo Manufacture - IM Woman Trial
Cyfeirnod: LSHTM-2021-29
II.1.2) Prif god CPV
33600000
II.1.3) Y math o gontract
Cyflenwadau
II.1.4) Disgrifiad byr
Manufacturing and packing of IMP for the IM Woman Trial due to commence in March 2023.
Three arms include experimental treatment (IM TXA), reference treatment/active control (IV TXA), and placebo control (0.9% sodium chloride solution).
Treatment Kit Boxes required for 4 campaigns with approximately 10,000 patient packs per campaign. Recruitment period is 24 months - campaign approximately once every 6 months.
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.1.7) Cyfanswm gwerth y caffaeliad
Gwerth heb gynnwys TAW: 1 066 444.00 GBP
II.2) Disgrifiad
II.2.2) Cod(au) CPV ychwanegol
33141310
33141320
33621000
33621200
33698000
39299100
44617100
79920000
II.2.3) Man cyflawni
Cod NUTS:
UKI31
Prif safle neu fan cyflawni:
LSHTM - Keppel Street, London WC1A 7HT
II.2.4) Disgrifiad o’r caffaeliad
Manufacturing and packing of IMP for the IM Woman Trial due to commence in March 2023.
A randomised, triple-blind, three-arm, non-inferiority trial to assess the efficacy and safety of intramuscular tranexamic acid compared to intravenous tranexamic acid and placebo in women having vvaginal and caesarean section births.
Three arms include experimental treatment (IM TXA), reference treatment/active control (IV TXA), and placebo control (0.9% sodium chloride solution).
Treatment Kit Boxes required for 4 campaigns with approximately 10,000 patient packs per campaign. Recruitment period is 24 months - campaign approximately once every 6 months.
II.2.5) Meini prawf dyfarnu
Maes prawf ansawdd: Technical
/ Pwysoliad: 70
Price
/ Pwysoliad:
30
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.1) Cyhoeddiad blaenorol mewn perthynas â’r weithdrefn hon
Rhif yr hysbysiad yn OJ S:
2021/S 000-029090
Section V: Dyfarnu contract
Rhif Contract: 1
Teitl: Investigational Medicinial Product (IMP) & Placebo Manufacture - IM Woman Trial
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
10/08/2023
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 1
Nifer y tendrau a ddaeth i law drwy ddulliau electronig: 1
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
Sharp Clinical Services (UK) Ltd
2234557
Unit 28, Heol Klockner
Rhymney
NP22 5RL
UK
E-bost: Rachel.curran@sharpclinical.com
NUTS: UK
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 1 066 444.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section VI: Gwybodaeth ategol
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
The Royal Courts of Justice
The Strand
London
WC2A 2LL
UK
VI.4.4) Y gwasanaeth lle y gellir cael gwybodaeth am y weithdrefn adolygu
London School of Hygiene & Tropical Medicine
Keppel Street
London
WC1E 7HT
UK
E-bost: procurement@lshtm.ac.uk
VI.5) Dyddiad anfon yr hysbysiad hwn
21/08/2023